阿霉素(ADR)是用于治疗乳腺癌的常用化学治疗剂。然而,多药耐药(MDR)可损害其在乳腺癌中的治疗效果。MDR的特征是P-糖蛋白(P-gp)外排泵的表达增加,抗凋亡蛋白的上调,和促凋亡蛋白的下调。因此,抑制ATP结合盒(ABC)转运蛋白被认为是克服MDR的最有效方法。在这项研究中,我们使用MTT(3-[4,5-二甲基噻唑-2-基]-2,5-二苯基四唑溴化物),西方印迹,流式细胞术,免疫荧光,并构建了异种移植瘤,以研究人参皂苷Rg3-近红外光热(Rg3-NIR)组合是否逆转了MCF-7/ADR乳腺癌的多药耐药性。体内和体外实验,结果表明,Rg3-NIR共同处理可有效诱导MCF-7/ADR乳腺癌细胞凋亡。这是通过逆转耐药相关蛋白的表达来实现的,同时也抑制细胞增殖,迁移,通过磷脂酰肌醇3-激酶(PI3K)/蛋白激酶B(AKT)信号传导途径的减弱,以及上皮-间质转化(EMT)过程。人参皂苷Rg3联合近红外光热治疗(NIR)可有效逆转乳腺癌MCF-7/ADR细胞的多药耐药,为乳腺癌耐药提供了新的治疗策略。
Adriamycin (ADR) is a frequently employed chemotherapeutic agent for the management of breast cancer. Nevertheless, multidrug resistance (MDR) can impair its therapeutic efficacy in breast cancer. MDR is characterized by increased expression of the P-glycoprotein (P-gp) efflux pump, up-regulation of anti-apoptotic proteins, and downregulation of pro-apoptotic proteins. Consequently, inhibition of ATP-binding cassette (ABC) transporter proteins has been deemed the most efficacious approach to overcome MDR. In this study, we used MTT (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide), Western blots, flow cytometry, immunofluorescence, and constructed xenograft tumors to investigate whether ginsenoside Rg3-near-infrared photothermal (Rg3-NIR) combination reversed multidrug resistance in MCF-7/ADR breast cancer. In vivo and in vitro experiments, the results showed that Rg3-NIR co-treatment was effective in inducing the apoptosis of MCF-7/ADR breast cancer cells. This was achieved by reversing the expression of drug resistance-associated proteins, while also inhibiting cell proliferation, migration, and epithelial-mesenchymal transition (EMT) processes via attenuation of the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) signaling pathway transduction. Ginsenoside Rg3 combined with near-infrared photothermal therapy (NIR) effectively reverses multidrug resistance in breast cancer MCF-7/ADR cells, providing a new therapeutic strategy for breast cancer drug resistance.